Favorable change of lipid profile after XXXX withdrawal.

@entity1 @entity410 @entity2812 @entity1092 @entity755 @entity8358 @entity302 @entity3174 @entity109 @entity2049 @entity165 @entity1851
OBJECTIVE: @entity1 treated with @entity2049 ( @entity8358 ) have increased serum levels of total @entity165 (TC), high-density lipoproteins (HDL), and low-density lipoproteins (LDL). We aimed to investigate whether these changes of serum lipids are reversible after @entity8358 withdrawal. MATERIAL AND METHODS: We used a prospective, randomized double-blinded design. A total of 160 @entity1 who had been @entity410 free on anti- @entity302 drug monotherapy for more than 2  years were included and randomized to withdrawal or not. The intervention was completed by 150 (80 females, 53%) patients. Serum samples from before and 4  months after completed withdrawal or no withdrawal were obtained from 130 @entity1 (63 females, 48%). Of these, 84 were treated with @entity8358 , 28 with @entity1092 , nine with @entity3174 , four with @entity109 , and five with @entity2812 . Of the @entity1 who had been treated with @entity8358 , 47 were randomized to the withdrawal group, and 37 were randomized to the non-withdrawal group. RESULTS: Among the @entity8358 -treated @entity1 , a significant decrease in serum levels of TC, LDL, and @entity755 ( @entity755 ) were found in the withdrawal group compared with the non-withdrawal group. Mean differences in change were as follows: TC 0.68  mmol/l (P  =  0.005, CL - 1.15 to -0.21); LDL - 0.67  mmol/l (P  =  0.001, CL - 1.03 to -0.29); @entity755 - 0.13  g/l (P  =  0.02, CL - 0.23 to -0.03). No significant changes in HDL, apolipoprotein A, and @entity1851 were detected. CONCLUSION: Our results indicate that @entity8358 may have unfavorable effects on serum levels of TC, LDL, and @entity755 . However, these changes seem to be reversible even after years of treatment.
